Avian #Influenza #Report: October 25 - 31 '26 (Wk 44) (HK CHP, November 3, 2026): 2 New Human Infections with #H5N1 virus in #USA & 2 cases with #H9N2 virus in #China

 

{Excerpts}

(...)

Avian influenza A(H5N1)

    ° Washington State:

        § The Washington State Department of Health reported the second and  third human infection with avian influenza A(H5N1) from Yakima County.

        § The second case, who had underlying health conditions, was  hospitalised with severe illness and passed away on November 1, 2026.

        § The third case has not experienced severe illness or been hospitalised.

        § Both cases had exposure to dairy cattle infected with avian influenza  A(H5N1) virus at local dairy farms.

(...)

Avian influenza A(H9N2):

    ° Hubei Province:

        § A two-year-old boy with onset on September 22, 2026.

    ° Jiangxi Province:

        § A 77-year-old woman with onset on September 16, 2026.

(...)

Source: Centre for Health Protection, Hong Kong PRC SAR, https://www.chp.gov.hk/files/pdf/2026_avian_influenza_report_vol22_wk44.pdf

____

#Identification and Characterization of #Wenshan #Mosquito Virus, a Putative Novel Bisegmented #RNA Virus from Mosquitoes in #Yunnan Province, #China

 

Abstract

Mosquito-associated viruses pose significant public health threats globally, with Yunnan Province in southwestern China representing a critical hotspot for arboviral emergence. In this study, 2612 female mosquitoes belonging to three species (Culex tritaeniorhynchus, Anopheles sinensis, and Culex quinquefasciatus) were collected from Wenshan during summer 2023. Viral metatranscriptomic analysis identified a novel bisegmented positive-sense single-stranded RNA virus, designated Wenshan mosquito virus (WSMV). Its genome comprises 4741 nucleotides across two segments: Segment 1 (3127 nt) encodes an S39 family peptidase and an RNA-dependent RNA polymerase (RdRp), while Segment-2 (1614 nt) encodes a capsid protein and a hypothetical protein. Pairwise nucleotide identity analysis revealed 87.62% and 86.96% identity with Hubei mosquito virus 2 (HMV-2) for Segments 1 and 2, respectively. Given the absence of established species demarcation criteria for this lineage, WSMV is described as a putative novel virus within the HMV-2-related group. Phylogenetic analyses using a common taxon set placed WSMV consistently with HMV-2 across both segments. WSMV was detected in Culex tritaeniorhynchus and Anopheles sinensis pools (MIR 2.08 and 1.54 per 1000, respectively), but not in the limited number of Culex quinquefasciatus pools tested; the host range of WSMV therefore remains to be fully defined. This study expands knowledge of mosquito-associated viral diversity in Yunnan’s border regions and provides a molecular foundation for future investigations.

Source: 

Link: https://doi.org/10.3390/v18111201

____

#Influenza at #human - #animal #interface - #Summary and #risk #assessment, 7 Sept. - 7 Oct. '26 (WHO, Oct. 28 '26): 1 New H5N1 case in #Cambodia, 4 #H9N2 in #China, 1 #H1N1v in #Brazil

• New human cases {2}: 

        ° From 7 September to 7 October 2026, based on reporting date,  detections of influenza A(H5N1) in one human, influenza A(H9N2) in four  humans and influenza A(H1N1) variant (A(H1N1)v) in one human were  officially reported.

• Circulation of influenza viruses with zoonotic potential in animals: 

    ° High pathogenicity avian influenza (HPAI) events in poultry and non- poultry animal species continue to be reported to the World Organisation for  Animal Health (WOAH).{3} The Food and Agriculture Organization of the United  Nations (FAO) also provides a global update on avian influenza viruses with  pandemic potential.{4} Additionally, low pathogenicity avian influenza viruses as  well as swine influenza viruses continue to circulate in animal populations.

• Risk assessment {5}: 

    ° There have been no reports of sustained human-to-human  transmission associated with the above-mentioned human infection events.  Based on information available at the time of this update, the overall public health  risk from currently known influenza A viruses detected at the human-animal interface has not changed and, at present, these viruses are not thought to be capable of sustained human-to-human transmission, although  this could change as they evolve. Whilst human infections with viruses of animal  origin are infrequent, they are not unexpected at the human-animal interface.

• Risk management: 

    ° Candidate vaccine viruses (CVVs) for zoonotic influenza viruses  intended for pandemic preparedness purposes, were reviewed and updated at the  September 2026 WHO consultation on influenza vaccine composition for use in the  Southern Hemisphere 2027 influenza season. A detailed summary of zoonotic  influenza viruses characterized since February 2026 is published and updated CVVs lists are published.

• IHR compliance {6}: 

    ° This includes any influenza A virus that has demonstrated the capacity to  infect a human, and its haemagglutinin (HA) gene (or protein) is not a mutated  form of those, i.e. A(H1) or A(H3), circulating widely in the human population.  Information from these notifications is critical to inform risk assessments for  influenza at the human-animal interface. 

Avian influenza viruses in humans

    ° A(H5N1), Cambodia

        § On 27 September 2026, Cambodia notified WHO of a laboratory- confirmed human infection with an avian influenza A(H5N1) virus in an adult  male, from Oddar Meanchey Province. He developed a runny nose on 24  September, and respiratory swabs collected that day tested positive for influenza A(H5N1) at the National Institute of Public Health on 26 September.  Institut Pasteur du Cambodge, a WHO H5 Reference Laboratory, confirmed the  result on 27 September. The patient was admitted to a referral Hospital for isolation, clinical monitoring and oseltamivir treatment. Genomic sequencing of  the virus from this case could not be done due to a low viral load.

    § The national and provincial Rapid Response Teams, in collaboration  with animal health and local authorities, are conducting epidemiological,  environmental and animal health investigations. The  patient frequently visited a family member’s poultry farm. At the farm, chickens began becoming ill and  dying around 13 September. Poultry specimens collected from remaining birds on 22 September tested positive for avian influenza.

    § Additional specimens were collected for testing from five direct contacts  with the case and three persons with poultry exposure and all were negative for  influenza A(H5N1). All identified contacts are being monitored for symptoms 14 days.

    § This is the sixth case reported in Cambodia in 2026.

    § According to reports received by WOAH, various influenza A(H5)  subtypes continue to be detected in wild and domestic birds in Africa, the  Americas, Asia, Europe and Oceania. Infections in non-human mammals are also reported, including in marine and land mammals.{7} A list of bird and mammalian species affected by HPAI A(H5) viruses is maintained by FAO.{8}

    ° Risk assessment for avian influenza A(H5N1) viruses:

        1. What is the current global public health risk of additional human cases of  infection with avian influenza A(H5N1) viruses?

            § Most human infections so far have been reported in people exposed to A(H5N1) viruses, for example, through contact with infected  poultry or contaminated environments, including live poultry markets, and  occasionally infected mammals and contaminated environments. As long as the  viruses continue to be detected in animals and related environments humans are  exposed to, further human cases associated with such exposures are expected but  remain unusual. 

            § The impact for public health if additional sporadic cases are detected is minimal. 

            § The current overall global public health risk is low.

        2. What is the likelihood of sustained human-to-human transmission of avian  influenza A(H5N1) viruses related to the events above?

            § No sustained human-to-human transmission has been identified  associated with the recent reported human infections with avian influenza  A(H5N1) viruses. There has been no reported human-tohuman transmission of  A(H5N1) viruses since 2007, although there may be gaps in investigations. In 2007 and the years prior, small clusters of A(H5N1) virus infections in humans  were reported, including some involving health care workers, where limited  human-to-human transmission could not be excluded; however, sustained human- to-human transmission was not reported. 

            § Current evidence suggests that influenza A(H5N1) viruses  related to these events did not acquire the ability to efficiently transmit  between people.

        3. What is the likelihood of international spread of avian influenza A(H5N1) viruses by travellers?

            § Should infected individuals from affected areas travel internationally,  their infection may be detected in another country during travel or  after arrival. If this were to occur, further community-level spread is  considered  unlikely as current evidence suggests these viruses have  not acquired the ability to transmit easily among humans.  

    ° A(H9N2), China

        § Between 9 and 30 September 2026, China notified WHO of four  laboratory-confirmed human cases of A(H9N2) virus infection.

        [Age - Province - Symptom onset]

        1} < 5-year-old - Henan - 30 August 2026

        2} < 5-year-old - Guangdong - 7 September 2026

        3} Adult - Henan - 17 September 2026

        4)} < 5-year-old - Guizhou - 20 September 2026

        § Three of the cases with mild symptoms were detected in influenza-like  illness surveillance and have recovered. The adult has underlying chronic conditions and was still in hospital at the time of reporting. 

        § All cases had direct or indirect exposure to poultry and/or local live  bird markets. Samples from environments associated with the likely area of  exposure of some of the cases tested positive for A(H9) viruses. 

        § No further cases were detected among contacts of these cases.

    ° Risk assessment for avian influenza A(H9N2):

        1. What is the global public health risk of additional human cases of infection  with avian influenza A(H9N2) viruses?

            § Most human cases follow exposure to the A(H9N2) virus through  contact with infected poultry or contaminated environments. Most human  infections of A(H9N2) to date have resulted in mild clinical illness. Since the virus  is endemic in poultry in multiple countries in Africa and Asia, additional human  cases associated with exposure to infected poultry or contaminated environments  are expected but remain unusual. The impact to public health if additional  sporadic cases are detected is minimal. The overall global public health risk is low.

        2. What is the likelihood of sustained human-to-human transmission of avian  influenza A(H9N2) viruses related to these events?

            § At the present time, no sustained human-to-human transmission  has been identified associated with the recently reported human  infections with A(H9N2) viruses. Current evidence suggests that A(H9N2) viruses  from these cases did not acquire the ability of sustained transmission among humans.

        

        3. What is the likelihood of international spread of avian influenza A(H9N2)  virus by travellers? 

            § Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel  or after arrival. If this were to occur, further community level spread is considered  unlikely as current evidence suggests the A(H9N2) virus subtype has not acquired  the ability to transmit easily among humans. Swine influenza viruses in humans

    ° Influenza A(H1N1)v, Brazil

        § On 30 September 2026, Brazil notified PAHO/WHO of a laboratory- confirmed human infection with an influenza A(H1N1)v virus in an adult woman, with pre-existing chronic conditions, residing in the state of Santa  Catarina. She developed symptoms of influenza-like illness on 16 July 2026 and  sought medical attention on 20 July. Her husband and three adult children,  who live in the same household, also experienced symptoms of an influenza-like illness; at that time, all were diagnosed, based solely on clinical  examination, with a viral infection and received treatment. The woman,  however, did not recover. On 27 July, the patient was hospitalized due to worsening respiratory symptoms. She received treatment, including the  antiviral oseltamivir, and required intensive care, including ventilatory support. Despite intensive care, the patient passed away on 28 August.

        § A nasopharyngeal sample, collected on 29 July, tested positive for  influenza A on 30 July and was subsequently subtyped as influenza A(H1N1) on 31  July. The sample was sent to the reference laboratory for respiratory viruses  at the Oswaldo Cruz Institute (IOC/Fiocruz) in Rio de Janeiro for further  characterization. On 4 September, genomic analysis identified an influenza  A(H1N1)v virus. 

        § According to information gathered during an epidemiological investigation conducted by municipal and state teams between 5 and 9  September, the patient had no history of travel or direct contact with  swine. However, a possible indirect exposure to swine was identified through  a neighbour who raises these animals for personal consumption.

        § Since 2015, twelve cases of human infection with swine-origin virus  variants, including this one, have been detected within Brazil’s respiratory virus  surveillance workflow. 

    ° Risk Assessment:

        1. What is the public health risk of additional human cases of infection with  swine influenza viruses?

            § Swine influenza viruses circulate in swine populations in many  regions of the world. Depending on geographic location, the genetic characteristics  of these viruses differ. Most human cases are exposed to swine  influenza viruses through contact with infected animals or contaminated environments. Human infection tends to result in mild clinical illness  in most cases. Since these viruses continue to be detected in swine  populations, further human cases are expected but remain unusual. The impact  for public health if additional cases are detected is minimal. The overall risk of additional human cases is low.

        2. What is the likelihood of sustained human-to-human transmission of  swine influenza viruses?  

            § No sustained human-to-human transmission was identified  associated with the event described above. Current evidence suggests that  contemporary swine influenza viruses have not acquired the ability of sustained  transmission among humans, therefore sustained human-to-human transmission  is thus currently considered unlikely.

        3. What is the likelihood of international spread of swine influenza viruses by  travelers?  

            § Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel  or after arrival. If this were to occur, further community level spread is considered  unlikely as current evidence suggest that these viruses have not acquired the ability to transmit easily among humans.

    For more information on zoonotic influenza viruses, see the report from  the WHO Consultation on the Composition of Influenza Virus Vaccines for Use in  the Southern Hemisphere Influenza Season that was held on 21-24 September 2026 at this link. 

Overall risk management recommendations:

    ° Surveillance and investigations

        • Due to the constantly evolving nature of influenza viruses, WHO  continues to stress the importance of global strategic surveillance in animals and  humans to detect virologic, epidemiologic and clinical changes associated with  circulating influenza viruses that may affect human (or animal) health. Continued  vigilance is needed within affected and neighbouring areas to detect infections in  animals and humans. Close collaboration with the animal health and environment  sectors is essential to understand the extent of the risk of human exposure and to prevent and control the spread of animal influenza. WHO has published  guidance on surveillance for human infections with avian influenza A(H5) viruses.

        • Epidemiologic and virologic surveillance and the follow-up of  suspected human cases should continue systematically. Guidance on investigation  of non-seasonal influenza and other emerging acute respiratory diseases has been  published on the WHO website.

        • Countries should increase avian influenza surveillance in domestic  and wild birds, enhance surveillance for early detection in cattle  populations in countries where HPAI is known to be circulating, include HPAI as a  differential diagnosis in non-avian species, including cattle and other livestock  populations, with high risk of exposure to HPAI viruses; monitor and investigate cases in non-avian species, including livestock, report cases of HPAI in  all animal species, including unusual hosts, to WOAH and other international  organizations, share genetic sequences of avian influenza viruses in publicly  available databases, implement preventive and early response measures to break  the HPAI transmission cycle among animals through movement restrictions of  infected livestock holdings and strict biosecurity measures in all holdings, employ  good production and hygiene practices when handing animal products, and protect persons in contact with suspected/infected animals. {7} More guidance can be  found from WOAH and FAO.

        • When there has been human exposure to a known outbreak of an  influenza A virus in domestic poultry, wild birds or other animals – or when there  has been an identified human case of infection with such a virus – enhanced  surveillance in potentially exposed human populations becomes necessary.  Enhanced surveillance should consider the health care seeking behaviour of the  population, and could include a range of active and passive health care and/or  communitybased approaches, including: enhanced surveillance in local influenza- like illness (ILI)/SARI systems, active screening in hospitals and of groups that  may be at higher occupational risk of exposure, and inclusion of other sources  such as traditional healers, private practitioners and private diagnostic laboratories.

        • Vigilance for the emergence of novel influenza viruses with  pandemic potential must be maintained at all times, including during a non- influenza emergency. To maximize the value of influenza surveillance platform for  other respiratory threats, WHO has updated and published practical guidance for integrated surveillance.

    

    ° Notifying WHO

        • All human infections caused by a new subtype of influenza virus are  notifiable under the International Health Regulations (IHR, 2005).{8,9} State  Parties to the IHR (2005) are required to  immediately notify WHO of  any laboratory-confirmed {10}  case of a recent human infection caused by an  influenza A virus with the potential to cause a pandemic {11}. Evidence of  illness is not required for this report. Evidence of illness is not required for this report.

        • WHO published the case definition for human infections with avian  influenza A(H5) virus requiring notification under IHR (2005): https://www.who.int/teams/global-influenzaprogramme/avian-influenza/case-definitions.

    ° Virus sharing and risk assessment

        • It is critical that these influenza viruses from animals or from humans are fully characterized in appropriate animal or human health influenza  reference laboratories. Under WHO’s Pandemic Influenza Preparedness (PIP)  Framework, Member States are expected to share influenza viruses with pandemic potential on a timely basis {12} with a WHO Collaborating Centre for influenza of GISRS. The viruses are used by the public health laboratories to assess the risk  of pandemic influenza and to develop candidate vaccine viruses.

        • The Tool for Influenza Pandemic Risk Assessment (TIPRA) provides  an in-depth assessment of risk associated with some zoonotic influenza viruses –  notably the likelihood of the virus gaining human-to-human transmissibility, and  the impact should the virus gain such transmissibility. TIPRA maps relative risk  amongst viruses assessed using multiple risk elements. The results of TIPRA  complement those of the risk assessment provided here, and those of prior TIPRA  risk assessments are published at http://www.who.int/teams/global-influenza-programme/avianinfluenza/tool-for-influenza-pandemic-risk-assessment-(tipra).

    ° Risk reduction

        • Given the observed extent and frequency of avian influenza in poultry, wild birds and some wild and domestic mammals, the public should  avoid contact with animals that are sick or dead from unknown causes, including  wild animals, and should report dead birds and mammals or request their removal by contacting local wildlife or veterinary authorities.

        • Eggs, poultry meat and other poultry food products should be  properly cooked and properly handled during food preparation. Due to the  potential health risks to consumers, raw milk should be avoided. WHO advises  consuming pasteurized milk. If pasteurized milk isn’t available, heating raw milk  until it boils makes it safer for consumption.

        • WHO has published practical interim guidance to reduce the risk of  infection in people exposed to avian influenza viruses.

    ° Trade and travellers

        • WHO advises that travellers to countries with known outbreaks of  animal influenza should avoid farms, contact with animals in live animal markets,  entering areas where animals may be slaughtered, or contact with any surfaces  that appear to be contaminated with animal excreta. Travelers should also wash  their hands often with soap and water. All individuals should follow good food  safety and hygiene practices.

        • WHO does not advise special traveller screening at points of entry or  restrictions with regards to the current situation of influenza viruses at the  human-animal interface. For recommendations on safe trade in animals and  related products from countries affected by these influenza viruses, refer to WOAH  guidance. 

Links:

    ° WHO Human-Animal Interface web page https://www.who.int/teams/global-influenza-programme/avian-influenza

    ° WHO Influenza (Avian and other zoonotic) fact sheet https://www.who.int/news-room/fact-sheets/detail/influenza-(avian-and-other-zoonotic)

    ° Global framework to accelerate action on avian  influenza https://iris.who.int/handle/10665/387613

    ° WHO Protocol to investigate non-seasonal influenza and other emerging acute  respiratory diseases https://www.who.int/publications/i/item/WHO-WHE-IHM-GIP-2018.2

    ° WHO Public health resource pack for countries experiencing outbreaks of  influenza in animals: https://www.who.int/publications/i/item/9789240076884

    ° Cumulative Number of Confirmed Human Cases of Avian Influenza A(H5N1)  Reported to WHO https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-a-h5n1-virus

    ° Avian Influenza A(H7N9) Information https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-influenza-a-(h7n9)-virus

    ° World Organisation of Animal Health (WOAH) web page: Avian Influenza https://www.woah.org/en/home/

    ° Food and Agriculture Organization of the United Nations (FAO) webpage:   Avian Influenza https://www.fao.org/animal-health/avian-flu-qa/en/

    ° WOAH/FAO Network of Expertise on Animal Influenza (OFFLU) http://www.offlu.org/

____

{1} This summary and assessment covers information confirmed during this  period and may include information received outside of this period.

{2} For epidemiological and virological features of human infections with animal  influenza viruses not reported in this assessment, see the reports on human cases  of influenza at the human-animal interface published in the Weekly  Epidemiological Record here.

{3} Avian influenza. Global situation. World Organisation for Animal Health  (WOAH) (https://www.woah.org/en/disease/avian-influenza/#ui-id-2).

{4} Global Avian Influenza Viruses with Zoonotic Potential situation update. Food  and Agriculture Organization of the United Nations (FAO)  (https://www.fao.org/animal-health/situation-updates/global-aiv-with-zoonoticpotential).

{5} Rapid risk assessment of acute public health events. World Health Organization; 2012 (https://iris.who.int/handle/10665/70810).

{6} Case definitions for the four diseases requiring notification in all  circumstances under the International Health Regulations (2005). World Health  Organization; 2009 (https://www.who.int/publications/m/item/casedefinitions-for-the-four-diseases-requiring-notification-to-who-in-all-circumstances-under-the-ihr-(2005)).

{7} World Organisation for Animal Health. Statement on High Pathogenicity Avian  Influenza in Cattle, 6 December 2024 (https://www.woah.org/en/high-pathogenicity-avian-influenza-hpai-in-cattle/).

{8} World Health Organization. International Health Regulations (2005), as  amended through resolutions WHA67.13 (2014), WHA75.12 (2022), and  WHA77.17 (2024) (https://apps.who.int/gb/bd/pdf_files/IHR_2014-2022-2024-en.pdf).

{9} World Health Organization. Case definitions for the four diseases requiring  notification in all circumstances under the International Health Regulations (2005)  (https://www.who.int/publications/m/item/casedefinitions-for-the-four-diseases-requiring-notification-to-who-in-all-circumstances-under-the-ihr-(2005)).

{10} World Health Organization. Manual for the laboratory diagnosis and  virological surveillance of influenza (2011)  (https://apps.who.int/iris/handle/10665/44518).

{11} World Health Organization. Pandemic influenza preparedness framework for  the sharing of influenza viruses and access to vaccines and other benefits, 2nd  edition (https://iris.who.int/handle/10665/341850).

{12} World Health Organization. Operational guidance on sharing influenza  viruses with human pandemic potential (IVPP) under the Pandemic Influenza  Preparedness (PIP) Framework (2017) (https://apps.who.int/iris/handle/10665/259402)

Source: 

Link: https://www.who.int/publications/m/item/influenza-at-the-human-animal-interface-summary-and-assessment--7-october-2026

____

Avian #Influenza #Report - October 11 - 17 '26 (Wk 42) (HK CHP, Oct. 20 '26): 1 New Human Case of #H5N1 Virus in the #US; 2 New #H9N2 Virus Cases in #China

 

{Excerpts}

(...)

Avian influenza A(H5N1)

    ° {USA} Washington:

        § The patient is currently isolating at home and has not experienced severe illness or required hospitalisation.

        § The case had exposure to dairy cattle infected with avian influenza A(H5N1) virus at a local dairy farm.

        § The Washington state recorded their first detection of avian influenza  A(H5N1) in two dairy farms on October 8, 2026.

Avian influenza A(H9N2)

    °{China} Guizhou Province:

        § A four-year-old boy with onset on September 20, 2026.

    ° Henan Province:

        § A 68-year-old man with onset on September 17, 2026.

(...)

Source: 

Link: https://www.chp.gov.hk/files/pdf/2026_avian_influenza_report_vol22_wk42.pdf

____

#China (People's Rep. of) - #Influenza A #H5 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 

{Extract}

(...)

An unspecified wild species bird in the Xizang Autonomous Province.

(...)

Source: 

Link: https://wahis.woah.org/#/in-review/7854

____

#HK CHP closely monitors case of #pneumonia of undetermined etiology that resulted in death in #Russia (Dept. of Health, Oct. 12 '26)

 

    Regarding the death of a laboratory worker in Irkutsk Oblast of Siberia, Russia, due to severe pneumonia of undetermined etiology, the Centre for Health Protection (CHP) of the Department of Health (DH) said today (October 12) that, according to the World Health Organization (WHO)'s latest announcement, information obtained from the Russian authorities indicated that no evidence of ongoing transmission associated with the event had been identified. 

    Nevertheless, for the sake of prudence, the CHP has implemented a series of control and prevention measures. 

    The CHP will continue to closely monitor the latest developments, respond swiftly, and strictly guard against imported cases in order to safeguard public health.

      After noticing media reports of the above-mentioned death case in Russia in early October, the CHP immediately and proactively sought further information from the WHO and the Russian health authorities. 

    According to the latest information from the WHO, citing data provided by Russian authorities, no case of plague had been recorded recently in Irkutsk Oblast, the laboratory testing of the deceased's contacts detected no high-threat pathogens, and that there were no further cases of severe pneumonia linked to this case. 

    The Russian authorities reported that no biosecurity incidents had occurred in the laboratory, and quarantine measures were instituted in the hospital where the patient was being treated. 

    According to the WHO's assessment, no evidence of ongoing transmission associated with this event has been identified so far. 

    Nevertheless, a key uncertainty remains the absence of a confirmed diagnosis in the deceased laboratory worker. 

    The WHO will continue to monitor the situation and assess any potential public health implications as further information becomes available.

      In recent months, the CHP has not received any reports of residents or travellers arriving in Hong Kong from Russia with cases of pneumonia of undetermined etiology. 

    Based on current information, there is no evidence indicating ongoing transmission. 

    The CHP assesses that the immediate public health impact to Hong Kong is low. 

    For the sake of prudence, the CHP has implemented a series of control and prevention measures to guard against imported cases, including:

          (i) strengthening health surveillance for passengers arriving on relevant flights from Russia at the airport, including arranging for Port Health Division officers to conduct temperature checks at the relevant flight gates, and conducting health assessments for passengers exhibiting symptoms;

          (ii) displaying signages and broadcasting announcements in the airport arrival area and through airlines to urge passengers who have visited Irkutsk Oblast of Siberia, Russia, within the past 14 days to proactively declare their travel history to the on-site staff of the DH for further health assessment;

          (iii) if an inbound traveller exhibits symptoms of pneumonia, after assessment by Port Health Division officers, arrangements will be made immediately to transfer the individual to a public hospital for further testing; and

          (iv) providing the Airport Authority Hong Kong and airlines with the latest information regarding the case in Russia, and urging airlines to remind their flight crews to strictly enforce established prevention and control measures if they identify suspected cases on their flights.

      Through existing mechanisms, Hong Kong has the capacity to detect cases of unexplained infections and emerging infectious diseases at boundary control points and in hospitals.

      In addition, the CHP will send letters to all doctors and hospitals in Hong Kong, reminding them to remain highly vigilant and to strengthen surveillance. Any patient who has visited Irkutsk Oblast of Siberia, Russia, within 14 days prior to the onset of symptoms and has developed pneumonia of undetermined etiology must immediately report to the CHP so that further testing can be arranged.

     　The CHP reminds travellers that if they develop respiratory symptoms after returning to Hong Kong, they should wear a face mask, seek medical attention and report their travel history to a doctor. The CHP will continue to maintain close liaison with the WHO and other relevant health authorities, closely monitor developments, and adjust disease prevention strategies as necessary to safeguard public health.

 

Ends/Monday, October 12, 2026 | Issued at HKT 16:25

NNNN

Source: 

Link: https://www.info.gov.hk/gia/general/202610/12/P2026101200466.htm?fontSize=1

____

Avian #Influenza #Report: September 20 - 26 '26 (Wk 39) (HK CHP, Sept. 29 '26): 1 New #H5N1 Human Case in #Cambodia, 2 New #H9N2 Cases in #China

 

{Excerpts}

(...)

    ° Avian influenza A(H5N1)

        § Oddar Meanchey Province:

            - The case involved a 49-year-old man.

            - He has been isolated in the hospital and is receiving intensive medical  care. 

            - The patient worked at a farm and had direct contact with sick and dead chickens which tested positive for avian influenza A(H5N1) virus.

(...)

    ° Avian influenza A(H9N2):

        § Guangdong Province:

            - A one-year-old girl with onset on September 7, 2026.

        § Henan Province:

            - A one-year-old girl with onset on August 30, 2026.

(...)

Source: 

Link: https://www.chp.gov.hk/files/pdf/2026_avian_influenza_report_vol22_wk39.pdf

____

Molecular evolutionary #dynamics of #coxsackievirus A16 in #Shenzhen, #China, 2012–2022

 

Highlights

    • A decade of CV-A16 molecular epidemiology in Shenzhen was analyzed.

    • Bayesian methods estimated the molecular evolutionary rate of CV-A16.

    • Transmission risk and evolutionary dynamics of CV-A16 in Shenzhen were assessed.

Abstract

Objectives

To investigate the epidemiological and genetic characteristics of coxsackievirus A16 (CVA16) associated with hand, foot and mouth disease (HFMD) in Shenzhen, China.

Methods

CVA16 was examined by a real-time RT-PCR method. Complete VP1 gene sequences of CVA16 strains were determined, and sequence analyses were performed using a series of bioinformatics programs.

Results

Of 6436 mild HFMD specimens collected between 2012 and 2022, 1395 (21.7%) were CVA16-positive, with annual detection rates ranging from 4.1% to 45.4% and peaking in 2018. Molecular phylogenetic analysis revealed the circulation of three CVA16 sub-genotypes (B1a, B1b and B3) in Shenzhen, China. The major sub-genotype was B1b from 2013 to 2019, while the sub-genotype B1a predominated in 2020-2022. Phylogenetic and sequence homology analyses suggested that re-emerging CVA16 B1a strains in Shenzhen originated from Vietnam and Thailand. The mean evolutionary rate of CVA16 strains circulating in Shenzhen was estimated at 3.604×10-3 substitutions per site per year. Distinct amino acid mutations in VP1 correlated with temporal shifts in Shenzhen's dominant CVA16 sub-genotypes: N14S/L23M for B1b, and T164K/V251I for the 2017–2022 re-emergent B1a.

Conclusion

In the post-EV-A71 vaccine era, CVA16 remains one of the major pathogens of HFMD in Shenzhen. Over the study period, the CVA16 sub-genotype in Shenzhen underwent a B1a→B1b→B1a turnover, which was associated with both imported lineages and local adaptive evolution. This study underscores the critical importance of continuous molecular surveillance for CVA16.

Source: 

Link: https://doi.org/10.1016/j.jcv.2026.105998

____

#Influenza at #human - #animal #interface - #Summary & #risk assessment, 8 Aug. - 6 Sept. '26 (WHO): 1 #H5N1 case in #Bangladesh, 3 #H9N2 cases in #China, 2 #H1N2v cases in #US

 

Influenza at the human-animal interface Summary and risk assessment, from 8 August to 6 September 2026 {1}

    • New human cases {2}: 

        ° From 8 August to 6 September 2026, based on reporting date,  detections of influenza A(H5N1) in one human and influenza A(H9N2) in  three humans were officially reported. Additionally, two human cases of infection with influenza A(H1N2) variant (A(H1N2)v) viruses were detected.

    • Circulation of influenza viruses with zoonotic potential in animals: 

        ° High pathogenicity avian influenza (HPAI) events in poultry and  non-poultry animal species continue to be reported to the World Organisation for  Animal Health (WOAH).{3} The Food and Agriculture Organization of the United  Nations (FAO) also provides a global update on avian influenza viruses with  pandemic potential.{4} Additionally, low pathogenicity avian influenza viruses as  well as swine influenza viruses continue to circulate in animal populations.

    • Risk assessment {5}: 

        ° There have been no reports of sustained human-to-human transmission associated with the above-mentioned human infection events.  Based on information available at the time of this update, the overall public health  risk from currently known influenza A viruses detected at the  human-animal interface has not changed and, at present, these viruses are  not thought to be capable of sustained human-to-human transmission, although  this could change as they evolve. Whilst human infections with viruses of animal  origin are infrequent, they are not unexpected at the human-animal interface.

    • IHR compliance {6}: 

        ° This includes any influenza A virus that has demonstrated the  capacity to infect a human, and its haemagglutinin (HA) gene (or protein) is not a  mutated form of those, i.e. A(H1) or A(H3), circulating widely in the human  population. Information from these notifications is critical to inform risk  assessments for influenza at the human-animal interface.

Avian influenza viruses in humans

A(H5N1), Bangladesh

    On 30 August, Bangladesh, through the national IHR focal point, notified WHO of one laboratory-confirmed human infection with an A(H5) virus in a  child from Rangpur division. 

    On 15 August 2026, the child developed a fever, cough and rhinitis and was  admitted to hospital on 17 August. 

    On 18 August, a nasopharyngeal swab and throat swab was collected as  part of hospital-based influenza surveillance and tested positive for influenza A(H5) by real-time RT-PCR at the icddr,b laboratory on the same day. 

    The sample was subsequently confirmed positive for influenza A(H5N1)  at the Molecular and Genomic Laboratory Department of Institute of Epidemiology,  Disease Control and Research (IEDCR) and National Influenza  Centre (NIC) of Bangladesh. 

    Genetic sequencing is underway. 

    The child remained hospitalized and was improving clinically at the time  of reporting.

    There was no reported history of travel outside the area of residence. The  child had a history of exposure to duck and chickens, including some that  were sick, in the household and adjacent households. 

    Poultry meat and oropharyngeal swab specimens collected from several  backyard chickens on 26 August tested negative for influenza A(H5).

    Close contacts were identified and placed under monitoring and all  contacts remained asymptomatic during the observation period, except for two heath care workers. 

    Respiratory specimens collected from these two individuals tested negative for influenza A viruses.

    This is the 4th laboratory-confirmed human case of avian influenza A(H5)  reported in Bangladesh in 2026.

    According to reports received by WOAH, various influenza A(H5) subtypes  continue to be detected in wild and domestic birds in Africa, the Americas, Asia,  Europe and Oceania. Infections in non-human mammals are also reported,  including in marine and land mammals.{7} A list of bird and mammalian species  affected by HPAI A(H5) viruses is maintained by FAO.{8}

Risk assessment for avian influenza A(H5N1) viruses:

    1. What is the current global public health risk of additional human cases of  infection with avian influenza A(H5N1) viruses?

        ° Most human infections so far have been reported in people exposed  to A(H5N1) viruses, for example, through contact with infected poultry or  contaminated environments, including live poultry markets, and occasionally  infected mammals and contaminated environments. As long as the viruses  continue to be detected in animals and related environments humans are exposed  to, further human cases associated with such exposures are expected  but remain unusual. The impact for public health if additional sporadic cases are detected is minimal. The current overall global public health risk is low.

    2. What is the likelihood of sustained human-to-human transmission of avian  influenza A(H5N1) viruses related to the events above?

        ° No sustained human-to-human transmission has been identified  associated with the recent reported human infections with avian  influenza A(H5N1) viruses. There has been no reported human-to-human transmission of A(H5N1) viruses since 2007, although there may be gaps in  investigations. In 2007 and the years prior, small clusters of A(H5N1) virus  infections in humans were reported, including some involving health care workers,  where limited human-to-human transmission could not be excluded;  however, sustained human-to-human transmission was not reported.  Current evidence suggests that influenza A(H5N1) viruses related to these events did not acquire the ability to efficiently transmit between people.

      3. What is the likelihood of international spread of avian influenza A(H5N1) viruses by travellers?

        ° Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel  or after arrival. If this were to occur, further community- level spread is  considered unlikely as current evidence suggests these viruses have  not acquired the ability to transmit easily among humans.  

A(H9N2), China

    Between 13 August and 1 September 2026, China notified WHO of three laboratory-confirmed human cases of A(H9N2) virus infection. 

(...)

    All cases had direct or indirect exposure to poultry and/or local live bird  markets. Samples from environments associated with the likely area of exposure  of some of the cases tested positive for A(H9) viruses. 

    No further cases were detected among contacts of these cases.

Risk assessment for avian influenza A(H9N2):

    1. What is the global public health risk of additional human cases of infection  with avian influenza A(H9N2) viruses?

        ° Most human cases follow exposure to the A(H9N2) virus through  contact with infected poultry or contaminated environments. Most human  infections of A(H9N2) to date have resulted in mild clinical illness. Since the  virus is endemic in poultry in multiple countries in Africa and Asia, additional human cases associated with exposure to infected poultry or  contaminated environments are expected but remain unusual. The impact to  public health if additional sporadic cases are detected is minimal. The  overall global public health risk is low.

    2. What is the likelihood of sustained human-to-human transmission of avian  influenza A(H9N2) viruses related to these events?

        ° At the present time, no sustained human-to-human transmission  has been identified associated with the recently reported human  infections with A(H9N2) viruses. Current evidence suggests that A(H9N2) viruses  from these cases did not acquire the ability of sustained transmission among humans.

    3. What is the likelihood of international spread of avian influenza A(H9N2)  virus by travellers?

        ° Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel  or after arrival. If this were to occur, further community level spread is considered  unlikely as current evidence suggests the A(H9N2) virus subtype has not acquired the ability to transmit easily among humans.

Swine influenza viruses in humans

Influenza A(H1N2)v, United States of America

    Since the risk assessment of 8 August 2026, two human infections with influenza A(H1N2v) viruses were detected in the state of Michigan.{7} 

    The patients, both <18 years of age, developed illness in the week of 15  August. They were not hospitalized and have recovered. Both attended the same agricultural fair where sick swine were present. The cases did not have  contact with each other and  no additional human infections with A(H1N2)v  viruses have been detected around this event. 

    Including these two cases, there have been a total of three human  infections with variant influenza A viruses reported in the United States in 2026.

Risk Assessment:

    1. What is the public health risk of additional human cases of infection with  swine influenza viruses?

        ° Swine influenza viruses circulate in swine populations in many  regions of the world. Depending on geographic location, the genetic characteristics  of these viruses differ. Most human cases are exposed to swine  influenza viruses through contact with infected animals or contaminated environments. Human infection tends to result in mild clinical illness  in most cases. Since these viruses continue to be detected in swine  populations, further human cases are expected but remain unusual. The impact  for public health if additional cases are detected is minimal. The overall risk of additional human cases is low.

    2. What is the likelihood of sustained human-to-human transmission of swine influenza viruses? 

        ° No sustained human-to-human transmission was identified  associated with the event described above. Current evidence suggests  that contemporary swine influenza viruses have not acquired the ability  of sustained transmission among humans, therefore sustained human-to-human  transmission is thus currently considered unlikely.

    3. What is the likelihood of international spread of swine influenza viruses by travelers? 

        ° Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel  or after arrival. If this were to occur, further community level spread is considered  unlikely as current evidence suggest that these viruses have not acquired the ability to transmit easily among humans.

Overall risk management recommendations:

Surveillance and investigations

    • Due to the constantly evolving nature of influenza viruses, WHO  continues to stress the importance of global strategic surveillance in animals and  humans to detect virologic, epidemiologic and clinical changes associated with  circulating influenza viruses that may affect human (or animal) health. Continued  vigilance is needed within affected and neighbouring areas to detect infections in  animals and humans. Close collaboration with the animal health and environment  sectors is essential to understand the extent of the risk of human exposure and to prevent and control the spread of animal influenza. WHO has published  guidance on surveillance for human infections with avian influenza A(H5) viruses.

    • Epidemiologic and virologic surveillance and the follow-up of suspected  human cases should continue systematically. Guidance on investigation of non- seasonal influenza and other emerging acute respiratory diseases has been  published on the WHO website.

    • Countries should increase avian influenza surveillance in domestic  and wild birds, enhance surveillance for early detection in cattle  populations in countries where HPAI is known to be circulating, include HPAI as a  differential diagnosis in non-avian species, including cattle and other livestock  populations, with high risk of exposure to HPAI viruses; monitor and investigate cases in non-avian species, including livestock, report cases of HPAI in  all animal species, including unusual hosts, to WOAH and other international  organizations, share genetic sequences of avian influenza viruses in publicly  available databases, implement preventive and early response measures to break  the HPAI transmission cycle among animals through movement restrictions of  infected livestock holdings and strict biosecurity measures in all holdings, employ  good production and hygiene practices when handing animal products, and protect  persons in contact with suspected/infected animals.{8} More  guidance can be found from WOAH and FAO.

    • When there has been human exposure to a known outbreak of an  influenza A virus in domestic poultry, wild birds or other animals – or when there  has been an identified human case of infection with such a virus – enhanced  surveillance in potentially exposed human populations becomes necessary.  Enhanced surveillance should consider the health care seeking behaviour of the  population, and could include a range of active and passive health care and/or  communitybased approaches, including: enhanced surveillance in local influenza- like illness (ILI)/SARI systems, active screening in hospitals and of groups that  may be at higher occupational risk of exposure, and inclusion of other sources  such as traditional healers, private practitioners and private diagnostic laboratories.

    • Vigilance for the emergence of novel influenza viruses with pandemic  potential must be maintained at all times, including during a non-influenza  emergency. To maximize the value of influenza surveillance platform for other  respiratory threats, WHO has updated and published practical guidance for integrated surveillance.

Notifying WHO

    • All human infections caused by a new subtype of influenza virus are  notifiable under the International Health Regulations (IHR, 2005).{9,10} State  Parties to the IHR (2005) are required to immediately notify WHO of any  laboratory-confirmed {11} case of a recent human infection caused by an influenza A virus with the potential to cause a pandemic {12}. Evidence of illness  is not required for this report. Evidence of illness is not required for this report.

    • WHO published the case definition for human infections with avian  influenza A(H5) virus requiring notification under IHR (2005):  https://www.who.int/teams/global-influenzaprogramme/avian-influenza/case-definitions.

Virus sharing and risk assessment

    • It is critical that these influenza viruses from animals or from humans are  fully characterized in appropriate animal or human health influenza reference  laboratories. Under WHO’s Pandemic Influenza Preparedness (PIP) Framework,  Member States are expected to share influenza viruses with pandemic potential on a timely basis {13} with a WHO Collaborating Centre for influenza of GISRS. The  viruses are used by the public health laboratories to assess the risk of pandemic influenza and to develop candidate vaccine viruses.

    • The Tool for Influenza Pandemic Risk Assessment (TIPRA) provides an  in-depth assessment of risk associated with some zoonotic influenza viruses –  notably the likelihood of the virus gaining human-to-human transmissibility, and  the impact should the virus gain such transmissibility. TIPRA maps relative risk  amongst viruses assessed using multiple risk elements. The results of  TIPRA  complement those of the risk assessment provided here, and those of prior TIPRA  risk assessments are published at http://www.who.int/teams/global-influenza-programme/avianinfluenza/tool-for-influenza-pandemic-risk-assessment-(tipra).

Risk reduction

    • Given the observed extent and frequency of avian influenza in poultry, wild birds and some wild and domestic mammals, the public should  avoid contact with animals that are sick or dead from unknown causes, including  wild animals, and should report dead birds and mammals or request their removal by contacting local wildlife or veterinary authorities.

    • Eggs, poultry meat and other poultry food products should be properly  cooked and properly handled during food preparation. Due to the potential health  risks to consumers, raw milk should be avoided. WHO advises consuming  pasteurized milk. If pasteurized milk isn’t available, heating raw milk until it boils makes it safer for consumption.

    • WHO has published practical interim guidance to reduce the risk of  infection in people exposed to avian influenza viruses.

Trade and travellers

    • WHO advises that travellers to countries with known outbreaks of  animal influenza should avoid farms, contact with animals in live animal markets,  entering areas where animals may be slaughtered, or contact with any surfaces  that appear to be contaminated with animal excreta. Travelers should also wash  their hands often with soap and water. All individuals should follow good food safety and hygiene practices.

    • WHO does not advise special traveller screening at points of entry or  restrictions with regards to the current situation of influenza viruses at the  human-animal interface. For recommendations on safe trade in animals and  related products from countries affected by these influenza viruses, refer to WOAH guidance.

Links:

    ° WHO Human-Animal Interface web page https://www.who.int/teams/global-influenza-programme/avian-influenza

    ° WHO Influenza (Avian and other zoonotic) fact sheet https://www.who.int/news-room/fact-sheets/detail/influenza-(avian-and-other-zoonotic)

    ° WHO Protocol to investigate non-seasonal influenza and other emerging acute respiratory diseases https://www.who.int/publications/i/item/WHO-WHE-IHM-GIP-2018.2

    ° WHO Public health resource pack for countries experiencing outbreaks of  influenza in animals: https://www.who.int/publications/i/item/9789240076884

    ° Cumulative Number of Confirmed Human Cases of Avian Influenza A(H5N1) Reported to WHO https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-a-h5n1-virus

    ° Avian Influenza A(H7N9) Information https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-influenza-a-(h7n9)-virus

    ° World Organisation of Animal Health (WOAH) web page: Avian Influenza https://www.woah.org/en/home/

    ° Food and Agriculture Organization of the United Nations (FAO) webpage:  Avian Influenza https://www.fao.org/animal-health/avian-flu-qa/en/

    ° WOAH/FAO Network of Expertise on Animal Influenza (OFFLU) http://www.offlu.org/

____

{1} This summary and assessment covers information confirmed during this  period and may include information received outside of this period.

{2} For epidemiological and virological features of human infections with animal  influenza viruses not reported in this assessment, see the reports on human cases  of influenza at the human-animal interface published in the Weekly Epidemiological Record here.

{3} Avian influenza. Global situation. World Organisation for Animal Health  (WOAH) (https://www.woah.org/en/disease/avian-influenza/#ui-id-2).

{4} Global Avian Influenza Viruses with Zoonotic Potential situation update. Food  and Agriculture Organization of the United Nations (FAO)  (https://www.fao.org/animal-health/situation-updates/global-aiv-with-zoonoticpotential).

{5} Rapid risk assessment of acute public health events. World Health  Organization; 2012 (https://iris.who.int/handle/10665/70810).

{6} Case definitions for the four diseases requiring notification in all  circumstances under the International Health Regulations (2005). World Health Organization; 2009 (https://www.who.int/publications/m/item/casedefinitions-for-the-four-diseases-requiring-notification-to-who-in-all-circumstances-under-the-ihr-(2005)).

{7} Weekly US Influenza Surveillance Report: Key Updates for Week 32, ending  August 15, 2026. US Centers for Disease Control and Prevention; 2026  (https://www.cdc.gov/fluview/surveillance/2026-week-32.html).

{8} World Organisation for Animal Health. Statement on High Pathogenicity Avian  Influenza in Cattle, 6 December 2024 (https://www.woah.org/en/high-pathogenicity-avian-influenza-hpai-in-cattle/).

{9} World Health Organization. International Health Regulations (2005), as  amended through resolutions WHA67.13 (2014), WHA75.12 (2022), and  WHA77.17 (2024) (https://apps.who.int/gb/bd/pdf_files/IHR_2014-2022-2024-en.pdf).

{10} World Health Organization. Case definitions for the four diseases requiring  notification in all circumstances under the International Health Regulations (2005)  (https://www.who.int/publications/m/item/casedefinitions-for-the-four-diseases-requiring-notification-to-who-in-all-circumstances-under-the-ihr-(2005)).

{11} World Health Organization. Manual for the laboratory diagnosis and  virological surveillance of influenza (2011) (https://apps.who.int/iris/handle/10665/44518).

{12} World Health Organization. Pandemic influenza preparedness framework for  the sharing of influenza viruses and access to vaccines and other benefits, 2nd  edition (https://iris.who.int/handle/10665/341850).

{13} World Health Organization. Operational guidance on sharing influenza  viruses with human pandemic potential (IVPP) under the Pandemic Influenza  Preparedness (PIP) Framework (2017) (https://apps.who.int/iris/handle/10665/259402).

Source: 

Link: https://www.who.int/publications/m/item/influenza-at-the-human-animal-interface-summary-and-assessment--6-september-2026

____